Business Context and Reporting Period
This Form 8-K Current Report was filed by Spero Therapeutics, Inc. on September 8, 2020. The filing primarily discloses positive topline results from the Phase 3 ADAPT-PO clinical trial for oral tebipenem HBr and the FDA acceptance of an Investigational New Drug (IND) application for SPR720.
Key Financial Metrics
This filing is a current report regarding clinical milestones and regulatory events. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Clinical Results
Tebipenem HBr (ADAPT-PO Trial)
- Primary Endpoint Met: The trial demonstrated statistical non-inferiority of oral tebipenem HBr versus IV ertapenem for complicated urinary tract infections (cUTI) and acute pyelonephritis (AP).
- Response Rates: Overall response rates at the test-of-cure visit were 58.8% for tebipenem HBr versus 61.6% for ertapenem (treatment difference -3.3%; 95% CI: -9.7, 3.2).
- Non-Inferiority Margin: The trial met the modified -12.5% non-inferiority margin and also met the original -10% margin (lower bound of 95% CI was -9.7).
- Clinical Cure: Rates were greater than 93% in both treatment groups.
- Safety Profile: Tebipenem HBr was well-tolerated in 1,372 patients. Treatment emergent adverse events (TEAEs) occurred in approximately 26% of patients in both groups. Serious TEAEs were infrequent (1.3% vs 1.7%). No deaths were reported.
- Specific Adverse Events: Three Clostridiodes difficile-associated TEAEs were observed in the ertapenem group; none were observed in the tebipenem HBr group.
SPR720
- Regulatory Status: The FDA accepted the IND application on August 31, 2020.
- Next Steps: The company expects to initiate a Phase 2a clinical trial for nontuberculous mycobacterial (NTM) pulmonary disease by year-end 2020.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- NDA Submission: Spero intends to initiate a rolling New Drug Application (NDA) submission for tebipenem HBr and anticipates completing the submission to the FDA in the second quarter of 2021.
- Data Presentation: Emerging data from the tebipenem HBr program will be presented at future scientific meetings and in publications.
- SPR720 Trial Design: The upcoming Phase 2a trial will enroll approximately 90 treatment-inexperienced patients with NTM pulmonary disease due to Mycobacterium Avium complex.
Risks and Contingencies
- Forward-Looking Statements: Actual results may differ due to the lengthy and uncertain drug development process, the need for additional funding, and reliance on third-party manufacturers.
- COVID-19 Impact: The pandemic influenced the modification of the non-inferiority margin and poses risks to trial completion and NDA submission timelines.
- Commercialization: Risks include market demand, pricing, payer access, and the ability to shift from IV to oral administration.
Investor Verification Checklist
- Verify the specific statistical analysis and confidence intervals for the ADAPT-PO trial in the attached Investor Presentation (Exhibit 99.1).
- Confirm the timeline for the rolling NDA submission and the anticipated Q2 2021 completion date.
- Review the detailed safety data, specifically regarding Clostridiodes difficile incidence, in the full clinical study report when available.
- Monitor the initiation date of the SPR720 Phase 2a trial to ensure it meets the year-end 2020 target.
- Assess the company's cash runway and funding requirements given the lack of revenue and the costs associated with NDA preparation and future trials.